Colman R W, Bradford H N, Warner A H
Thrombosis Research Center, Temple University School of Medicine, Philadelphia, PA 19140.
Thromb Res. 1989 Apr 15;54(2):115-23. doi: 10.1016/0049-3848(89)90041-8.
High molecular weight kininogen has been shown to be the principal plasma inhibitor of cellular thiol proteases including cathepsins B, H and L and calpains 1 and 2. Since these same enzymes have been reported to be elevated in animals with muscular dystrophy, we studied plasmas from hamsters with muscular dystrophy and compared these to normal hamster plasma. The ability of plasma to inhibit purified platelet calpain was assayed and found to be 62% of normal. Since low molecular weight kininogen can also inhibit calpain, the coagulant activity of kininogen, an activity unique for high molecular weight kininogen, was determined in dystrophic hamster plasma and found to be 69% of normal in close agreement with the calpain inhibitory activity. The contribution of the other plasma calpain inhibitor alpha 2-macroglobulin appeared small since inactivation with methylamine did not alter the ability to inhibit calpain in either normal or dystrophic plasma. We conclude that there is a selective deficiency of plasma high molecular weight kininogen in dystrophic hamsters, an abnormality which could play a role in the pathogenesis of this disorder.
高分子量激肽原已被证明是细胞硫醇蛋白酶的主要血浆抑制剂,这些蛋白酶包括组织蛋白酶B、H和L以及钙蛋白酶1和2。由于据报道这些相同的酶在患有肌肉萎缩症的动物中水平升高,我们研究了患有肌肉萎缩症的仓鼠的血浆,并将其与正常仓鼠血浆进行了比较。对血浆抑制纯化血小板钙蛋白酶的能力进行了测定,发现其为正常水平的62%。由于低分子量激肽原也能抑制钙蛋白酶,因此在营养不良仓鼠血浆中测定了激肽原的凝血活性(这是高分子量激肽原特有的活性),发现其为正常水平的69%,与钙蛋白酶抑制活性密切相关。另一种血浆钙蛋白酶抑制剂α2-巨球蛋白的贡献似乎很小,因为用甲胺灭活并不会改变正常或营养不良血浆中抑制钙蛋白酶的能力。我们得出结论,营养不良仓鼠的血浆中存在高分子量激肽原的选择性缺乏,这一异常可能在该疾病的发病机制中起作用。